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Nucleophosmin (NPM, B23, numatrin, NO38) is an abundant nucleolar phosphoprotein involved in multiple cellular functions.
Previous evidence indicates that high-level expression of NPM causes uncontrolled cell growth and suggests that NPM may have
oncogenic potential. In this study, we examined NPM expression in 103 paired cases of hepatocellular carcinoma (HCC), 12 cases of
hepatic focal nodular hyperplasia, 17 cases of liver tissue adjacent to a hepatic haemangioma, and series of array tissues from normal
human organs and malignancies using a monoclonal antibody against NPM and reverse transcription–PCR techniques, Western blot
analysis, immunohistochemistry, and immunocytofluorescence. Our data indicated that NPM expression was significantly higher in
HCC than in the non-malignant hepatocytes (Po0.001). Nucleophosmin was weakly expressed in hepatocytes from a 5-month-old
embryo and in stationary hepatocytes of healthy adults. Moreover, enhanced expression of NPM in HCC correlated with the level of
PCNA (R
2¼0.5639) and with the clinical prognostic parameters such as serum alpha fetal protein level, tumour pathological grading,
and liver cirrhosis (Po0.05). Our results suggest that NPM may play an important role in the progression of tumorigenesis and that
NPM may serve as a potential marker for HCC.
British Journal of Cancer (2007) 96, 477–484. doi:10.1038/sj.bjc.6603574 www.bjcancer.com
Published online 23 January 2007
& 2007 Cancer Research UK
Keywords: nucleophosmin; B23; hepatocellular carcinoma; PCNA; cell proliferation; malignancy
                                             
Hepatocellular carcinoma (HCC) is one of the most prevalent
malignancies worldwide, with an annual incidence of 250000
diagnoses. Although the process of hepatocarcinogenesis has not
yet been fully elucidated, it is considered a multifactorial and
multistep process that involves the activation of oncogenes or the
inactivation of tumour suppressor genes during the different
stages of HCC progression. Several studies have recently shown
that activation of oncogenes was involved in hepatocarcinogenesis,
genes such as cyclin D1 (Deane et al, 2001), the transcription factor
Yin Yang 1 (YY1) (Gordon et al, 2006), and the hedgehog pathway
(Sicklick et al, 2006). Overexpression of cyclin D1 has been shown
to be sufficient for the initiation of hepatocellular carcinogenesis
in a transgenic mouse model (Deane et al, 2001). The transcription
factor YY1 is considered to possess the potential to act as an
initiator of tumorigenesis and may serve as both a diagnostic and
prognostic tumour marker (Gordon et al, 2006). Overexpression
and tumorigenic activation of the Smoothened (SMO) proto-
oncogene mediates c-myc overexpression, suggesting that SMO
may also be a prognostic factor in HCC tumorigenesis (Sicklick
et al, 2006).
Nucleophosmin (NPM) is a major nucleolar phosphoprotein
implicated in multiple cellular functions, including ribosomal
protein assembly and transport (Verheggen et al, 2000; Huang
et al, 2005), centrosome duplication (Okuda et al, 2000; Okuda,
2002; Grisendi et al, 2005), molecular chaperone activity in
preventing protein aggregation (Hingorani et al, 2000; Szebeni
et al, 2003), and regulating the activity of the tumour suppressors
p53 (Colombo et al, 2002; Li et al, 2004; Maiguel et al, 2004) and
p14
ARF (Itahana et al, 2003; Bertwistle et al, 2004; Brady et al,
2004). Earlier studies have shown that the level of NPM is
markedly and promptly increased in association with cell
commitment to mitogenesis (Feuerstein and Mond, 1987; Feuer-
stein et al, 1988). It has also been shown that NPM is a direct target
of the Myc transcription factor during ribosomal biogenesis (Zeller
et al, 2001) and cyclin E/CDK2 kinase activity during centrosome
duplication (Okuda et al, 2000). Nucleophosmin physically
interacts with several other cellular factors such as the retino-
blastoma susceptibility gene product pRB (Takemura et al, 1994,
1999), the cell cycle G2–M checkpoint factor Gadd45a (Gao et al,
2005), and the tumour suppressor p14
ARF (Itahana et al, 2003).
Mounting evidence has linked excessive NPM to cellular transfor-
mation and ontogenesis (Pulford et al, 2001). Nucleophosmin
overexpression is frequently found in human cancers, including
cancers of the stomach (Tanaka et al, 1992), colon (Nozawa et al,
1996), bladder (Tsui et al, 2004), prostate (Subong et al, 1999),
thyroid (Onda et al, 2004), ovary (Zhang, 2004), and myeloid and
lymphoid cells (Schnittger et al, 2005). It has been shown that
overexpression of NPM in bladder cancer is independently
associated with cancer recurrence and progression to more
advanced stages, suggesting that NPM overexpression is an
important prognostic indicator for bladder cancer recurrence
(Tsui et al, 2004). Furthermore, ectopic overexpression of NPM in
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sNIH3T3 cells results in malignant transformation (Kondo et al,
1997). These findings further suggest that NPM is involved in the
regulation of cellular growth in various normal and neoplastic cells
and may be used as a clinical indicator for cancer patients.
The present study is aimed at investigating the potential roles of
NPM in HCC using a systematic analysis on the levels of NPM in a
large number of human HCC and non-malignant liver lesions, in
normal human adult and embryo tissues, and to address the
correlation between NPM expression and the clinical parameters.
MATERIALS AND METHODS
Nucleophosmin recombinant protein and monoclonal
antibody
Human NPM was PCR amplified from cDNA (catalogue no.
MHS1011-58590, clone ID: 2821577, OpenBioSystem, Huntsville,
AL, USA) using specific primers according to NPM1 gene source
sequence (50-cgcggatccgaagattcgatggacatggac and 30-cccaagcttaa
gagacttcctccactgcca). The gene was then cloned into the Pqe30
vector (catalogue no. 33203, Qiagen, Valencia, CA, USA) and
expressed in an Escherichia coli expression system to obtain
recombinant NPM protein. The purified recombinant protein was
used to generate a monoclonal antibody using routine hybridoma
cell techniques. The titre and specificity of the antibodies were
analysed and characterised by Western blot analysis and
immunocytofluorescene. A PCNA monoclonal antibody was
purchased (Zymed, South San Francisco, CA, USA).
Clinical samples and tissue arrays
Samples from 132 cases with liver disease and their clinical
material were collected from the files of the Cancer Center of Sun
Yat-Sen University, Guangzhou, China. These cases included 103
cases of HCC, 12 cases of hepatic focal nodular hyperplasia (FNH),
and 17 cases of hepatic haemangiomas. All of the tissue blocks
were sectioned for immunohistochemistry of NPM and PCNA. Ten
paired cases of HCC tissue along with the adjacent hepatic tissue
from the tissue bank department of this cancer centre were
collected for reverse transcription–PCR (RT–PCR) and Western
blot analyses. Another tissue array with sections from multiple
organs, including normal and diseased tissues for immunohisto-
chemistry, was purchased from Cybrdi Biotech Co (catalogue no.
CC00-11-002, CC00-11-003, CC00-01-004, EC01-01-006, NC03-01-
001, Cybridi, Xian City, China). This array included normal adult
tissues; normal embryo tissues (5 months); diseased tissues,
including malignancies from liver, brain, lung, kidney, stomach,
colon, breast, cervix, prostate, and skin; as well as cells from
different origins such as epithelia, non-epithelia, and lymphocytes.
All of the human specimens in the study were approved by the
Independent Ethics Committee of the Cancer Center of Sun
Yat-Sen University.
Cell culture, immunocytofluorescence, and Western blot
analysis
Six hepatoma cell lines including Hep G2, Huh-7, PLC/PRF/5, SK-
Hep-1, Chang, and Hep-3B were cultured as reported previously
(Yun et al, 2003; Miao et al, 2006). Briefly, for immunocytofluo-
rescence, the cultured cells were fixed for 10min and rinsed with
PBS. The cells were then incubated with the primary monoclonal
antibody (NPM, 1:1000) overnight, followed by incubation with a
fluorescence-conjugated secondary antibody for 1h, and finally
dehydrated and mounted. The fluorescent signal was observed
under fluorescent microscopy (Yun et al, 2003). For immunolabel-
ling, lysates from the tissue samples were prepared as reported
previously (Yun et al, 2003; Miao et al, 2006). One hundred
micrograms of each lysate was separated by SDS–PAGE. The
proteins were transferred onto blotting membranes. After block-
ing, the membranes were incubated overnight with mouse
monoclonal antibody against NPM, rabbit polyclonal antibody
against PCNA (FL-261, Santa Cruz Inc., Santa Cruz, CA, USA), and
mouse monoclonal antibody against GAPDH (Kangchen Biotech,
Shanghai, China) (NPM, 1:2000; PCNA, 1:1000; GAPDH, 1:1000),
followed by incubation with a horseradish peroxidase-conjugated
IgG. The blots were then visualised with an ECL kit (Amersham
Life Science, Piscataway, NH, USA) and exposed for 30s (NPM)
and 1min (PCNA, GAPDH) to X-ray film. The bands were
analysed using the Quantity Onet Software (Bio-Rad, Hercules,
CA, USA).
Reverse transcriptase–PCR
Total RNA was extracted from 10 paired samples of frozen HCC
tissue and adjacent hepatic tissue using the Trizol method (Gibco,
Carlsbad, CA, USA) according to the manufacturer’s instructions.
One microgram of RNA sample was reverse transcribed with
oligo(dT)15 primers (Promega, Madison, WI, USA) to obtain
single-stranded cDNA. One-tenth of the product was used as
template in PCR amplification for 28 cycles in a thermal cycler.
Each cycle consisted of 30s denaturation at 94.51C, 30s annealing
at 551C, and 1min extension at 721C. Under these conditions, the
amplifications occurred in a linear exponential phase. The
following primers were used: NPM forward, 50-CAC CCG ATG
GAA GAT TC-30; NPM reverse, 50-GGA CAG CCA GAT ATC AAC
T-30; G3PDH forward, 50-AAA TCC CAT CAC CAT CTT CC-30; and
G3PDH reverse, 50-TCC ACC ACC CTG TTG CTG TA-30. The PCR
products were analysed by 1.0% agarose gel electrophoresis. The
abundance of PCR signals was determined using the Quantity
Onet Software (Bio-Rad, Hercules, CA, USA).
Immunohistochemistry
One hundred thirty-two sample blocks were sectioned for
immunohistochemistry of NPM and PCNA. The above tissue array
sections were prepared for immunohistochemistry of NPM with a
three-step immunoperoxidase method using a Strept-Avidin Biotin
kit (Dakopatts, Glostrup, Denmark) as previously described (Yun
et al, 2003, 2004). Briefly, after blocking, the sections were
incubated in primary antibodies overnight (NPM, 1:400; PCNA,
1:400), followed by incubation in secondary antibodies, and
further incubation with the Strept-Avidin Biotin complex
(Dakopatts, Denmark). Reactivity was developed in chromogen
DAB solution. After contrast staining, the sections were dehy-
drated and mounted. A brown particle in a cell was considered as
positive labelling. These sections were observed under light
microscopy and the staining intensities were assessed by two
pathologists – Dr JP Yun and Dr J Xiang.
Statistical analysis
After immunohistochemistry of NPM and PCNA of tissue from
cases with liver diseases, four types of nuclear staining intensities
were discovered. These were classified as strongly positive
(þþþ), intermediately positive (þþ), weakly positive (þ),
or negative ( ). For each case, 1000 cells in one case were
randomly selected and counted, scoring for these four intensities.
For factor analysis, the percentages of the four intensities were
transformed to one Ridit value for each case that was representa-
tive of the NPM or PCNA expression intensity. The usual tests
(comparison of means, t-test, and one-way ANOVA) were then
used to analyse the differences of NPM or PCNA expression among
the different groups. The Pearson correlation was employed to
examine the relationship between NPM and PCNA expression.
Statistical significance was initially set at Po0.05.
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Nucleophosmin expression in the HCC tissues
In seven out of 10 cases, NPM mRNA expressions were higher in
HCC tissues than in the paired liver tissue adjacent to the tumours
(samples 2–5 and 7–9), as determined by RT–PCR (Figure 1). In
three cases, NPM expressions of the HCC tissues were found to be
lower than those in the adjacent healthy tissues (samples 1 and 10)
and nearly same as that in the adjacent healthy tissue (sample 6).
The expression levels of NPM in these samples with HCC were on
average 1.31-fold higher than in the paired healthy tissue. These
results indicated that NPM mRNA was expressed at a higher level
in HCC than in the hepatocytes adjacent to the tumour.
For use in immunolabelling studies, NPM monoclonal anti-
bodies were raised against recombinant NPM protein (with a
molecular weight of approximately 35kDa) and characterised by
Western blot and immunocytofluorescence (Figure 2). In total, one
clone was screened to produce specific monoclonal antibodies
against NPM that were used to immunolabel this protein in
Western blot analysis, immunofluorescence, and immunohisto-
chemistry.
Nucleophosmin protein expressions in the above 10 paired
samples were analysed by Western blot analysis. In seven out of 10
samples, expression of this protein was apparently higher in HCC
tissues than in the liver tissue adjacent to the tumour; however,
there was no apparent difference of expression in three cases. The
mean expression level of the HCC samples was 1.88-fold higher
than the paired liver tissue. The expression pattern of NPM was
similar to that of PCNA (Figure 3A). These results indicate that
NPM protein is expressed at a higher level in HCC than in
hepatocytes adjacent to the tumour.
The subcellular expression of NPM was determined by
immunocytofluorescence. It was found to localise predominantly
in the nucleoli of six cultured cell lines and weakly in the nuclei of
some cells such as Hep G2, PLC/PRF/5, SK-Hep-1, and Hep-3B
(Figure 3B). This may suggest that NPM functions primarily in the
nuclei of these cultured hepatoma.
Expression of NPM and/or PCNA in HCC and non-
malignant liver diseases
As shown in Figures 4 and 5, NPM was more highly expressed in
HCC (group 1), as determined by immunohistochemistry, was
mainly located in the nuclei of the cancer cells, and was higher
than that in the hepatocytes with non-malignant diseases (groups
2–4) in staining intensity or the total positive cell number.
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Figure 2 Characterisation of NPM antibodies. (A) The identity of NPM
recombinant protein (1mg) was verified by Western blot analysis with an
anti-NPM antibody. (B) The immunoreactivity of NPM protein to different
antibodies (10ng per lane) was analysed by Western blot using preimmune
serum (lane 1), an anti-His antibody (1:4000, lane 2), or anti-NPM
antibody (1:2000, lane 3). The recombinant NPM proteins were detected
by His antibody or NPM antibody, but not by the preimmune serum. (C)
Immunocytofluorescence analysis using NPM antibodies. Image 1: cultured
Hep B3 cells were stained with preimmune serum; image 2: the same cells
as in image 1 were stained with DAPI; image 3: cultured Hep B3 cells were
stained with anti-NPM antibodies; image 4: the same cells as in image 3
were stained with DAPI. (All fields  400.)
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Figure 3 Nucleophosmin protein expression was detected in clinical
samples with HCC by Western blot analysis and immunocytofluorescence.
(A) Higher expression of NPM was found in HCC tissue samples (T3–5,
T7, and T9) than in the corresponding adjacent tissue (N3–5, N7, and N9).
This was similar to the PCNA expression trend in the same samples. As a
control, GAPDH was used. (B) Nucleophosmin subcellular localisation was
also examined in these cells. Hep 3B (image 1), PLC/PRF/5 (image 2), Huh-
7 (image 3), Hep G2 (image 4), SK-Hep-1 (image 5), and Chang (image 6).
(All fields,  400.)
MN 1 T1 N2 T2 T3 T4 T5 N6 N3 N4 N5 T6 N7 N8 N9 N10T10
NPM
GAPDH
0.23 1.42 1.22 1.67 1.07 2.01 1.91 1.41 1.39 0.73 T/N ratio
T7 T8 T9
Figure 1 Nucleophosmin expression was detected in clinical samples
with HCC by RT–PCR. Ten paired samples of HCC tissue and the
corresponding liver tissue adjacent to the tumour were used. Samples T1–
10 are HCC tissues, whereas N1–10 designate the corresponding adjacent
healthy tissue samples. M: marker. Expression of the housekeeping gene,
GAPDH, serves as a control.
Increased expression of NPM/B23 in HCC
J-P Yun et al
479
British Journal of Cancer (2007) 96(3), 477–484 & 2007 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sCounting the positive cells, scored for the four staining intensities,
the median percentages of NPM expression in these groups are
listed in Figure 5A.
The PCNA expression levels in the four groups were also
determined and analysed by immunohistochemistry (Figures 4 and
5). It was found that PCNA labelling in the cancer cells with HCC
was stronger than in the hepatocytes with non-malignant diseases.
The median percentages of PCNA expression divided into the four
groups are listed in Figure 5B.
To statistically compare NPM or PCNA expression among
the four groups, staining intensity group percentages were
transformed to Ridit values representative of NPM or PCNA
expression in each case. The mean Ridit values of NPM or
PCNA expressions in the four groups are listed in Table 1. There
were significant statistical differences of NPM and PCNA
expressions among the four groups by ANOVA analysis
(P¼0.000). Using the Student –Newman–Keuls analysis, NPM
or PCNA expressions in HCC were significantly higher than in
non-malignant diseases (Po0.05).
We also calculated the correlation of the mean Ridit values of
NPM and PCNA expression by Pearson correlation analysis
(Figure 6). There was statistical correlation between NPM and
PCNA expression in the four groups (R
2¼0.5639).
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Figure 4 Nucleophosmin expression was observed in HCC and non-
malignant diseases by immunohistochemistry and compared to PCNA
expression. Nuclear expression of both NPM and PCNA was stronger in
the HCC tumour cells than in hepatocytes with non-malignant diseases.
Images A and B: immunoreactivity of NPM (A) and PCNA (B) in the
tumour cells with HCC; images C and D: immunoreactivity of NPM (C)
and PCNA (D) in the hepatocytes adjacent to the tumours with HCC;
images E and F: Immunoreactivity of NPM (E) and PCNA (F)i n
hepatocytes with nodular hepatic hyperplasia; images G and H:
immunoreactivity of NPM (G) and PCNA (H) in hepatocytes adjacent
to tumours with haemangioma. All sections were counterstained with
haematoxylin. (All fields  400.)
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Figure 5 The staining intensities of NPM and PCNA were measured and
calculated among the four groups including HCC and non-malignant liver
diseases. (A) The median staining intensity percentages of NPM nuclear
expression in the four groups are shown. (B) The median percentages of
PCNA staining intensity in the four groups are shown.
Table 1 Comparison of NPM and PCNA expressions among the four groups
NPM expression PCNA expression
ANOVA ANOVA
Cases Ridit (mean7s.d.) F-value P-value Ridit (mean7s.d.) F-value P-value
Group 1 103 0.29570.115 0.42970.107
Group 2 103 0.67970.087 0.62470.084
Group 3 12 0.60370.097 0.60870.085
Group 4 17 0.70870.065 285.14 0.000* 0.65070.048 87.184 0.000*
Total 235 0.50970.214 0.54070.135
NPM¼nucleophosmin; PCNA¼proliferative cell nuclear antigen; ANOVA¼analysis of variance. Group 1: HCC; group 2: hepatocytes adjacent to the tumours with HCC;
group 3: hepatocytes in the lesions with focal nodular hyperplasia; group 4: hepatocytes adjacent to the tumours with haemangioma. *Statistically significant (Po0.01).
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with clinical parameters
We further investigated the differences of NPM or PCNA
expression in 103 cases of HCC based on different clinical
parameters, including the patient’s sex, age, clinical TNM stage,
tumour size, tumour amount, serum level of alpha fetal protein
(AFP), histological grade, and the presence or absence of liver
cirrhosis. These cases were divided into two groups for each
clinical parameter (Marrero et al, 2005). The mean Ridit values of
each group for each clinical parameter were measured by Ridit
analysis and are shown in Table 2. The differences in the Ridit
values for the two groups of each clinical parameter were analysed
by t-test analysis. Significant statistical differences were found for
three of the clinical parameters, including serum level of AFP,
histological grade, and presence of liver cirrhosis (Po0.05). These
data indicate that the levels of NPM expression in HCC correlate
with the grading of the tumour, and thus upregulation of NPM
may be involved in tumour progression. There were no statistical
differences with respect to NPM expression in the HCC cases with
the other clinical parameters including patient’s sex, age, clinical
TNM stage, tumour size, and tumour amount (P40.05).
The differences of PCNA expression in the HCC cases based on
the same clinical parameters were analysed and are shown in
Table 2. We found no statistical differences in PCNA expression in
the HCC cases with these clinical parameters (P40.05).
Nucleophosmin expression in human normal adult and
embryo tissues
To evaluate the potential role of NPM in normal human cells, we
investigated NPM expression in normal human adult and embryo
tissues (5 months) by tissue array and immunohistochemistry.
As shown in Figure 7, NPM expressions in different tissues were
not quite consistent either in staining intensity or in location.
Nucleophosmin was expressed in some cells from adults that did
not express this protein in embryos. There were three types of
NPM subcellular labelling: one was predominantly located in
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Figure 6 Potential correlations with NPM and PCNA expression were
statistically analysed among the four groups including HCC and non-
malignant liver diseases. Pearson correlation of NPM and PCNA expression
revealed a correlation of expression among the four groups (R
2¼0.5639).
Table 2 NPM and/or PCNA expressions in HCC with clinical parameters
NPM expression (mean7s.d.) PCNA expression (mean7s.d.)
Cases (n) Ridit value T-value P-value Ridit value T-value P-value
Sex 103
Male 96 0.29470.107 0.43170.104
Female 7 0.22970.141 1.53 0.129 0.39070.150 0.713 0.501
Age 103
o50 61 0.29170.110 0.41870.100
X50 42 0.28870.112 0.165 0.87 0.44470.117 1.202 0.508
TNM stage
a 89
I–II 30 0.31270.102 0.44370.110
III–IV 59 0.27570.111 1.542 0.127 0.42870.100 0.677 0.5
Tumour size 103
o5cm 35 0.30970.108 0.43070.114
X5cm 68 0.280070.111 1.248 0.215 0.42870.105 0.105 0.707
Tumour amount 103
1 80 0.30070.110 0.43270.103
X2 23 0.25470.108 1.787 0.077 0.41870.125 0.516 0.607
Serum AFP 89
o20ngml
 1 27 0.32370.107 0.44570.085
X20ngml
 1 62 0.27270.107 2.088 0.04* 0.42870.110 0.734 0.366
HBsAg 89
Positive 82 0.28470.109 0.43170.106
Negative 7 0.32670.108 0.982 0.329 0.45170.065 0.491 0.313
Histological grade
b 103
I 16 0.34970.092 0.46170.088
II–IV 87 0.27970.111 2.376 0.019* 0.42370.110 1.325 0.161
Liver cirrhosis 103
Yes 73 0.27470.103 0.43070.111
No 30 0.32870.120 2.145 0.037* 0.42670.101 0.152 0.88
NPM¼nucleophosmin; PCNA¼proliferative cell nuclear antigen; HCC¼hepatocellular carcinoma; AFP¼alpha fetal protein.
aTNM stage was based on the UICC criteria
published in 1997.
bHistological grade was with reference to WHO classification published in 2000. *Statistically significant (Po0.05).
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mainly in the nuclei, such as in the epidermis, epithelia, glands,
and proliferating lymphocytes located in the germinal centres
(Figure 7D–H); the third type showed mainly cytoplasmic
staining, such as in mitotic and some non-mitotic cells, such as
adult cerebral neuronal cells (Figure 7C) and the epithelial cells of
the kidney’s proximal tubule (Figure 7G), embryo osteoblasts, and
thymic cells. Interestingly, there was only very weak labelling of
NPM in the hepatocytes from normal embryo livers (Figure 7B)
and expression was found in the nucleolus and nucleus of the
embryo brain cells (Figure 7D). Differential expression of NPM in
normal human cells demonstrated that it may correlate with cell
proliferation and differentiation.
Nucleophosmin expression in cancer tissue
To evaluate the potential role of NPM in the human malignancies,
we further investigated NPM expression in different cancer tissues
by immunohistochemistry on tissue arrays. Strong nuclear
expression of NPM was found in carcinomas originating from
stratified epithelia derived from several organs, including the skin,
oesophagus, cervix, and lung, in carcinomas from glandular
epithelia from the breast, thyroid gland, lung, digestive tract,
ovary, and prostate, and in other malignancies such as B-cell
lymphoma, renal cell carcinoma, and glioblastoma. However, we
observed only nucleolar expression and weak nuclear expression
in Wilms’ tumour of kidney. The NPM expressions in eight
different malignancies originated from eight different organs are
shown in Figure 8. In general, stronger nuclear staining of NPM
expressions in the malignancies was observed as compared to
those in the corresponding normal tissues (Figure 7; data not
shown). Put together, NPM expression detected in human
malignancies implicated a potentially important role for NPM in
tumorigenesis and development.
DISCUSSION
The present study revealed four principal findings: (1) that NPM is
differentially expressed, either in quantity or subcellular location, in
malignant human liver cancer (HCC) compared to hepatocytes with
non-malignant liver diseases. Similar differences in PCNA expres-
sion were detected among these cases. These results indicate that
AB
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GH
Figure 7 Nucleophosmin expression was detected in human adult and
embryo tissues from different organs by immunohistochemistry. (A) Adult
liver, (B) embryo liver, (C) adult brain, (D) embryo brain, (E) adult small
intestine, (F) embryo small intestine, (G) adult kidney, and (H) embryo
kidney. We observed different subcellular localisation of NPM in human
cells, such as in the nucleoli of hepatocytes in normal adult liver (A), the
nuclei of epithelia and glands (D–F and H), and the cytoplasm of adult
cerebral neuronal cells (C) and epithelial cells of the kidney proximal tubule
(G). There was very weak labelling in embryo liver hepatocytes (B). A
greater magnification of the stained cells selected from the corresponding
image is shown as inset. All sections are counterstained with haematoxylin.
(All fields,  400; inset images,  1000.)
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Figure 8 Nucleophosmin expression was observed in different types of
human malignancies by immunohistochemistry. (A) Poorly differentiated
squamous cervical carcinoma, (B) pulmonary squamous carcinoma, (C)
adenocarcinoma of the small intestine, (D) adenocarcinoma of the
prostate, (E) B-cell lymphoma of the testis, (F) astrocytoma of the brain,
(G) thyroid papillary carcinoma, and (H) Wilms’ tumour of the kidney.
Strongly stained NPM nuclear expression was observed in the tumour cells
of many malignancies (A–G), whereas only weakly stained nuclear
expression was found in the Wilms’ tumour sample (H). All sections are
counterstained with haematoxylin. (All fields  400.)
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of HCC. We also found that (2) in the cases with HCC, NPM
overexpression was correlated with clinical parameters, such as
serum AFP level, tumour pathological grading, and cirrhosis,
suggesting that NPM might serve as a potential marker for HCC. (3)
Nucleophosmin was differently expressed either in quantity or in
subcellular location in normal human liver and other tissues when
adult and embryo tissues were compared. The NPM expression of
normal human cells was shown to correlate with cell proliferation
and differentiation. Lastly, (4) NPM was found to be highly
expressed in multiple cancers from different organs derived from
either epithelial or non-epithelial origins. This NPM expression in
multiple human malignancies implicates that NPM might play an
important role in tumorigenesis and development.
The present study examined the potential role of NPM in HCC.
Our data revealed a high level of NPM expression in the majority of
HCC examined. Overexpression of NPM in HCC may thus represent
an acquired phenotypic feature. Furthermore, there was a positive
correlation between NPM expression and tumour pathological
grading or HCC with liver cirrhosis. Therefore, NPM may be an
important factor in the development of HCC. Previous studies
showed that NPM seemed to be associated with both oncogenic
activity and tumour suppression. Hence, overexpression of NPM in
NIH3T3 cells resulted in malignant transformation (Kondo et al,
1997). Nucleophosmin nuclear overexpression in colon adenoma/
carcinoma seems also to be associated with adenoma/carcinoma
progression (Nozawa et al, 1996). It has been shown that NPM
overexpression was present in several human solid tumours,
including gastric cancer (Tanaka et al, 1992), colon cancer (Nozawa
et al, 1996), bladder cancer (Tsui et al, 2004), prostate cancer
(Subong et al, 1999), thyroid cancer (Onda et al,2 0 0 4 ) ,a n do v a r y
cancer (Zhang, 2004). Interestingly, a recent review reported that
NPM overexpression in tumour cells led to increased proliferation
and inhibition of apoptosis and was involved in human tumori-
genesis (Grisendi et al, 2006).
The present study also demonstrated that there were similarities of
NPM nuclear expression and PCNA expression between HCC and
non-malignant diseases. We recently observed that NPM expression
in rat hepatocytes increased quantitatively and changed in
subcellular location during liver regeneration after partial hepatec-
tomy. Moreover, these alterations of hepatocyte NPM level were
consistent with different phases of the cell cycle and the level of
PCNA (Yun et al, 2002, 2003). Yung’s group has recently shown that
the expression of NPM correlates with PCNA expression. They
demonstrated that the increased NPM resulted in enhanced DNA
repair ability and rescued cells from UV killing (Wu et al, 2002).
They further provided evidence that ectopic overexpression of NPM
caused a marked upregulation in the amounts of PCNA and YY1 (a
multifunctional transcriptional factor) proteins. Nucleophosmin
regulates the PCNA promoter through YY1 (Weng and Yung, 2005).
Another interesting finding in this study is that there are
different subcellular locations of NPM in the normal cells of the
embryo and the adult. We describe three types of NPM cellular
distribution found in normal human adult or embryo tissues – the
nucleoli, nuclei, or the cytoplasm. Differential subcellular expres-
sion of NPM in normal human cells may correlate with cell
proliferation and differentiation. Previous reports have shown that
NPM is involved in the assembly and/or intranuclear transport
of pre-ribosomal particles and in cytoplasmic/nuclear trafficking
(Spector et al, 1984; Yung et al, 1985; Borer et al, 1989). In mitotic
cells, most nuclear proteins were dispersed throughout the
cytoplasm, including NPM, which then re-localised to the centro-
somes, and later to each daughter cell that received one centrosome
bound by NPM after mitosis (Okuda et al, 2000). Interestingly, we
also found that some of the non-mitotic cells, such as adult cerebral
neuronal cells, epithelial cells of the adult kidney proximal tubule,
and embryo osteoblast and thymic cells contain cytoplasmic NPM.
The functional significance and the mechanism behind this
cytoplasmic localisation remain to be determined. Previous studies
found that two isoforms of NPM, termed B23.1 and B23.2, were
expressed in different subcellular locations of human cells and
possessed different functions (Chang and Olson, 1990; Umekawa
et al, 2001). B23.1 was primarily localised in nucleoli, where it was
likely targeted to rRNA-rich nucleoli, possibly owing to its RNA-
binding activity, whereas B23.2 was localised in the nucleoli and
also throughout the nucleoplasm; the function of B23.2 is not yet
well understood. These two proteins are identical except for the C-
terminal 35 amino acids observed in B23.1 that is absent in B23.2.
The expression level of B23.2 was much lower than that of B23.1.
Interestingly, the expression level of B23.1 was closely correlated
with the cell growth rate, whereas that of B23.2 remained relatively
constant (Wang et al, 1993).
Another previous study demonstrated the cytoplasmic location of
NPM and the mutation of exon 12 of the NPM1 gene as a hallmark
of a large subgroup of primary acute myelogenous leukaemia
(NPMcþ AML) (Falini et al, 2005). However, we have not observed
cytoplasmic NPM in any of the 103 cases of HCC or other cancers in
the tissue array used in the present study. The cytoplasmic location
in the solid cancers will be worthy of further study.
Both polyclonal and monoclonal antibodies to NPM have been
reported in the past, but only a few immunocytochemical analyses
or distribution studies of NPM in human tissues have confirmed
its ubiquitous expression in both normal and neoplastic cells
(Nozawa et al, 1996; Cordell et al, 1999; Subong et al, 1999). The
study describes monoclonal antibodies that detect NPM in
paraffin-embedded tissue array samples and confirms NPM
distribution within different cells.
Altogether, the present study provides evidence that NPM may
be involved in hepatocarcinogenesis and serve as a potential
marker for applied clinicopathology in HCC.
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